
Figure S1. Risk survival status plot of acceptor sites (AA) model in thyroid cancer patients.



15 Survival time (years) 10 100 200 300 400 500 Patients (increasing risk socre) 10 Risk score 400 500 100 200 300 Patients (increasing risk socre) LUC7L|32849|AD SRSF5|28161|AD 0.2 CDK11A|214|AD AGR2|78873|AD PUS1|25231|AD MYL12A|44492|AD IRF5|81734|AD

Figure S2. Risk survival status plot of alternate donor sites (AD) model in thyroid cancer patients.

Figure S3. Risk survival status plot of alternate promoter (AP) model in thyroid cancer patients.




Figure S4. Risk survival status plot of alternate terminator (AT) model in thyroid cancer patients.




Figure S5. Risk survival status plot of exon skipping (ES) model in thyroid cancer patients.




Figure S6. Risk survival status plot of exclusive exons (ME) model in thyroid cancer patients.




Figure S7. Risk survival status plot of retained intron (RI) model in thyroid cancer patients.




Figure S8. Risk survival status plot of all model in thyroid cancer patients.

